(secondQuint)Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb).

 This is a prospective, randomized, double-blind, 5-period incomplete unbalanced crossover, placebo and active comparator (open-label) controlled, multicenter clinical trial to assess the efficacy and safety of three doses of formoterol fumarate (6 1/2g, 12 1/2g and 24 1/2g) BID administered via Pressair(R) compared to placebo and to open-label formoterol fumarate (20 1/2g BID and 40 1/2g single dose) administered as an inhalation solution via a standard jet nebulizer (with a mouthpiece) connected to an air compressor (Perforomist(R) Inhalation Solution).

 The drug product is an inhalation powder comprising of micronized aclidinium bromide and micronized formoterol fumarate with -lactose monohydrate as the carrier, presented in a breathactuated device-metered dry-powder inhaler (DPI).

 It has been approved under the trademarks of Genuair(R) and/or Pressair(R) in some territories.

.

 Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)@highlight

To assess the bronchodilation of three doses of formoterol fumarate (6 1/2g, 12 1/2g and 24 1/2g) twice daily (BID) administered via Pressair(R) compared to placebo and to open-label nebulized formoterol fumarate (20 1/2g and 40 1/2g).

